Stock ONCOTHYREON INC (USA)
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Oncothyreon Inc (USA) Nasdaq

Equities

US6823241087

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Cascadian Therapeutics Announces 2018 Outlook and Recent Progress
GL
Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency
GL
Cascadian Therapeutics Added to the Nasdaq Biotechnology Index
GL
Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer
GL
Cascadian Therapeutics Reports Third Quarter 2017 Financial Results
GL
Cascadian Therapeutics to Report Third Quarter 2017 Financial Results on November 8, 2017
GL
Cascadian Therapeutics to Participate in Panel Discussions at Two Conferences in November
GL
Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal Cancer
GL
Cascadian Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
GL
Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress
GL
Cascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology (ESMO) 2017 Congress
GL
Cascadian Therapeutics Reports Second Quarter 2017 Financial Results
GL
Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on August 8, 2017
GL
Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in Europe
GL
Oncothyreon USA : Cascadian Therapeutics' Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases
PU
Cascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases
GL
Cascadian Therapeutics to Present at Jefferies 2017 Healthcare Conference
GL
Cascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for Today at 8:30 a.m. ET
GL
Cascadian Therapeutics to Report First Quarter 2017 Financial Results on May 9, 2017
GL
Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for Cancer Research Annual Meeting 2017
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. Stock
  5. News Oncothyreon Inc (USA)